(Knoxville, TN, UNITED STATES) April 11, 2013– ABT Molecular Imaging, Inc., in Knoxville, TN, has successfully achieved the installation and clinical use of its next-generation Biomarker Generator by the Sveta Marina University Hospital in Bulgaria. ABT’s next-generation product integrates a compact accelerator and micro-chemistry with integrated quality control, for single-dose biomarker production.

Abdominal CT images taken for any reason, that include the lumbar spine, can be used for the additional purpose of identifying patients with osteoporosis, according to a study published April 16 in Annals of Internal Medicine.

Eli Lilly and Company has acquired a pair of PET tracers from Siemens. The investigational tracers are designed to target the tau deposits that are the hallmark of Alzheimer’s disease. Avid Radiopharmaceuticals, Lilly’s wholly owned subsidiary, will develop and validate the tracers, according to Lilly.

Eli Lilly and Company (NYSE: LLY) today announced it has acquired two investigational positron emission tomography (PET) tracers from Siemens Medical Solutions USA, Inc. The tracers are intended to image tau (or neurofibrillary) tangles in the brain, one of two known hallmarks of Alzheimer's disease. Based on studies of samples obtained at autopsy, the amount and location of tau tangles in an Alzheimer's disease patient's brain is thought to correlate with the severity of the disease. There are currently no approved diagnostics to detect tau tangles in living patients, creating challenges for scientists working to understand the progression of the disease and how therapies may impact it.

Researchers are developing a method of quantitative myocardial perfusion imaging that analyzes myocardial perfusion reserve using SPECT with advanced cadmium zinc telluride crystal detectors to unlock extent of coronary artery disease, according to a study published April 11 by The Journal of Nuclear Medicine.

Advancing age and worsening comorbidity were associated with fewer prostate biopsies after abnormal PSA screening results; however, biopsy-detected cancer often led to treatment regardless of age, comorbidity or cancer status, according to a study published online April 15 in the Journal of the American Medical Association.

A prostate cancer patient has become the first person in the world to be treated using the latest version of Varian's Vitesse™ real time planning solution for planning and performing advanced high-dose-rate (HDR), ultrasound-guided brachytherapy treatments. The treatment took place at the Levine Cancer Institute in Charlotte, North Carolina.

The Royal Liverpool University Hospital’s interventional radiology department has recently invested in two SonoSite EDGE® hand-carried ultrasound systems to assist diagnosis and treatment of disease.